Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Type 2 diabetes
Current treatment with oral antidiabetes drugs (OADs) for at least 2 months
HbA1c between 7.0-11.0% if on OAD monotherapy
HbA1c between 7.0-10.0% if on OAD combination therapy
BMI less than or equal to 40 kg/m2
You may not be if
Current regular smoking or regular smoking within the last 6 months
Current acute or chronic pulmonary disease (except for asthma)
Proliferative retinopathy requiring treatment
Clinically significant disease history including kidney or liver disease, or heart disease which limits physical activity or results in discomfort with physical activity
Pregnancy
Clareo Health | Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
